RS61993B1 - Cmv vakcine - Google Patents

Cmv vakcine

Info

Publication number
RS61993B1
RS61993B1 RS20210759A RSP20210759A RS61993B1 RS 61993 B1 RS61993 B1 RS 61993B1 RS 20210759 A RS20210759 A RS 20210759A RS P20210759 A RSP20210759 A RS P20210759A RS 61993 B1 RS61993 B1 RS 61993B1
Authority
RS
Serbia
Prior art keywords
cmv
seq
glycoprotein
viral vector
replication
Prior art date
Application number
RS20210759A
Other languages
English (en)
Serbian (sr)
Inventor
Klaus Orlinger
Karen Lingnau
Thomas Monath
Farshad Guirakhoo
Gerhard Fuhrmann
Katherine Cohen
Vera Baumgartl-Strasser
Andreas Aspöck
Manuela Kainer
Bernhard Brim
Bettina Kiefmann
Elizabeth Watson
Mario Aistleithner
Katharina Bayer
Elsa Mühlbacher
Original Assignee
Hookipa Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech Gmbh filed Critical Hookipa Biotech Gmbh
Publication of RS61993B1 publication Critical patent/RS61993B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20210759A 2013-12-03 2014-12-03 Cmv vakcine RS61993B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361911135P 2013-12-03 2013-12-03
US201462055699P 2014-09-26 2014-09-26
PCT/EP2014/076466 WO2015082570A1 (en) 2013-12-03 2014-12-03 Cmv vaccines
EP14820762.4A EP3077519B1 (en) 2013-12-03 2014-12-03 Cmv vaccines

Publications (1)

Publication Number Publication Date
RS61993B1 true RS61993B1 (sr) 2021-07-30

Family

ID=52232138

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210759A RS61993B1 (sr) 2013-12-03 2014-12-03 Cmv vakcine

Country Status (17)

Country Link
US (3) US10111945B2 (OSRAM)
EP (2) EP3077519B1 (OSRAM)
JP (2) JP6818551B2 (OSRAM)
CN (2) CN115058452A (OSRAM)
AU (2) AU2014359276B2 (OSRAM)
CA (1) CA2932318C (OSRAM)
CY (1) CY1124288T1 (OSRAM)
DK (1) DK3077519T3 (OSRAM)
ES (1) ES2868427T3 (OSRAM)
HR (1) HRP20211015T1 (OSRAM)
HU (1) HUE054579T2 (OSRAM)
LT (1) LT3077519T (OSRAM)
PL (1) PL3077519T3 (OSRAM)
PT (1) PT3077519T (OSRAM)
RS (1) RS61993B1 (OSRAM)
SI (1) SI3077519T1 (OSRAM)
WO (1) WO2015082570A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2438773T3 (es) 2007-12-27 2014-01-20 Universität Zürich Vectores arenavíricos defectuosos en la replicación
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
PL3077519T3 (pl) * 2013-12-03 2021-10-18 Hookipa Biotech Gmbh Szczepionki CMV
US10722564B2 (en) 2014-11-13 2020-07-28 Université de Genéve Tri-segmented arenaviruses as vaccine vectors
EP3031822A1 (en) * 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
CA2987155A1 (en) 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
JP6921833B2 (ja) 2015-10-22 2021-08-18 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
IL314371A (en) * 2015-11-04 2024-09-01 Hookipa Biotech Gmbh Vaccines against hepatitis B virus
PT3373959T (pt) 2015-11-12 2022-08-09 Hookipa Biotech Gmbh Partículas de arenavírus como vacinas contra o cancro
WO2017156146A1 (en) * 2016-03-08 2017-09-14 University Of Vermont And State Agricultural College Modified arenavirus
KR102574810B1 (ko) 2016-04-15 2023-09-08 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 습성 연령 관련 황반 변성의 치료를 위한 조성물
AU2017345766A1 (en) * 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
JP2019533690A (ja) 2016-11-04 2019-11-21 ホオキパ バイオテック ジーエムビーエイチ 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子
UY37679A (es) 2017-04-14 2018-11-30 Regenxbio Inc Tratamiento de mucopolisacaridosis ii con iduronato-2-sulfatasa (ids) humana recombinante producida por células neurales o gliales humanas
WO2018204080A1 (en) * 2017-05-02 2018-11-08 The Scripps Research Institute Compositions and methods related to arenavirus immunogens
JP2021535730A (ja) * 2018-05-11 2021-12-23 シティ・オブ・ホープCity of Hope 複数の部位メガロウイルス（ｃｍｖ）抗原の発現のためのｍｖａベクター及びその使用
JP7584405B2 (ja) 2018-10-17 2024-11-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変されたサイトメガロウイルスタンパク質及び安定化された複合体
CN113164585B (zh) * 2018-12-10 2023-08-29 Km生物医薬股份公司 用于预防或治疗巨细胞病毒的先天性感染的疫苗
US20220380805A1 (en) 2019-11-07 2022-12-01 Universität Basel Arenaviruses as vectors
KR102837045B1 (ko) * 2020-06-09 2025-07-23 케이엠 바이올로직스 가부시키가이샤 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
RU2756557C1 (ru) * 2020-11-02 2021-10-01 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Способ опосредованного определения титра вируса ящура в неинактивированном сырье для вакцины при амплификации вирусной нуклеиновой кислоты и детекции РНК-ампликонов с применением технологии молекулярных биконов
US20240117328A1 (en) 2021-02-10 2024-04-11 Regenxbio Inc. Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
US20240229073A1 (en) 2021-05-13 2024-07-11 Hookipa Biotech Gmbh Arenaviruses as vectors
WO2024163912A2 (en) * 2023-02-03 2024-08-08 The Children's Medical Center Corporation Vaccine and therapeutic protein delivery compositions comprising fusion proteins
WO2025056782A1 (en) 2023-09-15 2025-03-20 Hookipa Biotech Gmbh Arenavirus formulations, methods and uses thereof
CN118221773B (zh) * 2024-02-05 2025-09-09 首都医科大学附属北京儿童医院保定医院 与HLA相关的CMV pp65表位疫苗组合物与应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
DE68929478T2 (de) * 1988-01-29 2004-04-29 Aventis Pasteur Rekombinante CMV-Neutralisierungsproteine
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP1655305A3 (en) * 2000-03-21 2006-09-13 Genzyme Corporation Therapeutic anti-cytomegalovirus compounds
DE102004034461B4 (de) * 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
CA2597921A1 (en) * 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
US8173657B2 (en) 2006-03-23 2012-05-08 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2007109812A2 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
ES2438773T3 (es) * 2007-12-27 2014-01-20 Universität Zürich Vectores arenavíricos defectuosos en la replicación
US8580276B2 (en) * 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
JP2012530500A (ja) * 2009-06-26 2012-12-06 ヴェクトライト バイオメディカ インコーポレイテッド サイトメガロウイルス由来のペプチドを含む免疫原組成物および使用方法
WO2012049317A2 (en) * 2010-10-15 2012-04-19 Glaxosmithkline Biologicals S.A. Novel antigen
JP2014502848A (ja) 2011-01-07 2014-02-06 バイオサイエンス・スロバキア ウイルス診断
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
CA2840989A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
US8834307B2 (en) 2011-10-06 2014-09-16 Kawasaki Jukogyo Kabushiki Kaisha Belt type continuously variable transmission
EP2766385A2 (en) * 2011-10-12 2014-08-20 Novartis AG Cmv antigens and uses thereof
CN104853771A (zh) * 2012-07-06 2015-08-19 诺华股份有限公司 巨细胞病毒蛋白的复合物
WO2014140301A1 (en) 2013-03-15 2014-09-18 Université De Genève Anti-mycobacterial vaccines
PL3077519T3 (pl) 2013-12-03 2021-10-18 Hookipa Biotech Gmbh Szczepionki CMV
US10722564B2 (en) * 2014-11-13 2020-07-28 Université de Genéve Tri-segmented arenaviruses as vaccine vectors
CA2987155A1 (en) 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
IL314371A (en) 2015-11-04 2024-09-01 Hookipa Biotech Gmbh Vaccines against hepatitis B virus
PT3373959T (pt) 2015-11-12 2022-08-09 Hookipa Biotech Gmbh Partículas de arenavírus como vacinas contra o cancro
IL314272A (en) 2016-05-18 2024-09-01 Hookipa Biotech Gmbh Three-segmented PICHINDE viruses as vaccine vectors
JP2019533690A (ja) 2016-11-04 2019-11-21 ホオキパ バイオテック ジーエムビーエイチ 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子
AU2018247958A1 (en) 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors
US20220380805A1 (en) 2019-11-07 2022-12-01 Universität Basel Arenaviruses as vectors
MX2022014725A (es) 2020-05-29 2023-02-09 Hookipa Biotech Gmbh Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus.

Also Published As

Publication number Publication date
WO2015082570A8 (en) 2015-11-26
PT3077519T (pt) 2021-05-13
US20160296619A1 (en) 2016-10-13
HK1226440A1 (zh) 2017-09-29
CN115058452A (zh) 2022-09-16
JP2017503482A (ja) 2017-02-02
CY1124288T1 (el) 2022-07-22
EP3077519A1 (en) 2016-10-12
EP3077519B1 (en) 2021-03-31
EP3904522A1 (en) 2021-11-03
US20230181725A1 (en) 2023-06-15
PL3077519T3 (pl) 2021-10-18
CA2932318C (en) 2023-10-10
US20190247493A1 (en) 2019-08-15
DK3077519T3 (en) 2021-06-14
CN105980570B (zh) 2022-06-07
CN105980570A (zh) 2016-09-28
AU2014359276B2 (en) 2021-01-28
HRP20211015T1 (hr) 2021-10-01
AU2014359276A1 (en) 2016-06-16
JP2021061848A (ja) 2021-04-22
SI3077519T1 (sl) 2021-07-30
US11554169B2 (en) 2023-01-17
WO2015082570A1 (en) 2015-06-11
CA2932318A1 (en) 2015-06-11
HUE054579T2 (hu) 2021-09-28
AU2021202541A1 (en) 2021-05-27
JP6818551B2 (ja) 2021-01-20
ES2868427T3 (es) 2021-10-21
JP7001807B2 (ja) 2022-02-04
LT3077519T (lt) 2021-04-26
US10111945B2 (en) 2018-10-30

Similar Documents

Publication Publication Date Title
US20230181725A1 (en) Cmv vaccines
AU2021232660B2 (en) HPV vaccines
TWI777093B (zh) 非洲豬瘟病毒疫苗
Paillot et al. Equine herpes virus-1: virus, immunity and vaccines
Colombage et al. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus
JP2020533367A (ja) Ｒｓｖに対する免疫の安全な誘導方法
US20230323389A1 (en) Synthetic modified vaccinia ankara (smva) based coronavirus vaccines
WO2023023940A1 (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
US11976305B2 (en) Lassa vaccine
HK40063367A (en) Cmv vaccines
WO2021178844A1 (en) Zika and flavivirus immunogenic compositions and their use
HK1226440B (en) Cmv vaccines
RU2828676C2 (ru) Вакцина против вируса африканской чумы свиней
US20240226283A9 (en) Vaccination of hematopoietic stem cell donors with cytomegalovirus triplex composition
OA19870A (en) Lassa vaccine.
Chen CD8 T cell immunity elicited with DNA vaccination
Morabito Intranasal Vaccination with Murine Cytomegalovirus Expressing Respiratory Syncytial Virus Antigens Promotes Tissue-resident Memory CD8+ T cells